Biocon Completes Phase I Trial For Lantus Biosimilar, As Speculation Builds On Deal For Oral Insulin
06:36 EDT 26 Jul 2012 | Elsevier Business Intelligence
A steadily developing pipeline β including a biosimilar of Sanofiβs blockbuster diabetes therapy Lantus β is starting to bear fruit. Meanwhile, speculation is building that Biocon is close to partnering its oral insulin IN-105, with Bristol-Mye..
Original Article: Biocon Completes Phase I Trial For Lantus Biosimilar, As Speculation Builds On Deal For Oral Insulin
More From BioPortfolio on "Biocon Completes Phase I Trial For Lantus Biosimilar, As Speculation Builds On Deal For Oral Insulin"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
